Skip to main content

Advertisement

Table 1 KEGG and GO enrichment analysis

From: miRNAs and sports: tracking training status and potentially confounding diagnoses

Category Database Target genes on category Expectation value Enrichment p value
Melanoma KEGG 17 3.7 4.6 3.10E−06
Bladder cancer KEGG 13 2.4 5.4 1.36E−05
Cell cycle KEGG 19 5.3 3.6 1.83E−05
Glioma KEGG 15 3.4 4.4 1.83E−05
G1_phase(4) & mitotic_G1_phase(5) GO 11 1.3 8.3 2.34E−05
Viral carcinogenesis KEGG 20 6.0 3.3 2.59E−05
Pancreatic cancer KEGG 16 4.1 4.0 2.72E−05
Chronic myeloid leukemia KEGG 17 4.6 3.7 3.04E−05
Non-small cell lung cancer KEGG 12 3.1 3.9 5.86E−04
p53 signaling pathway KEGG 11 3.2 3.4 3.44E−03
Thyroid cancer KEGG 6 1.4 4.3 2.67E−02
Biological_phase(2) GO 15 4.9 3.1 4.68E−02
Cell_cycle_phase(3)&mitotic_cell_cycle_phase(4) GO 15 4.6 3.3 4.68E−02
Cell_maturation(5) GO 14 4.2 3.3 4.68E−02
Regulation_of_fibroblast_proliferation(5) GO 12 3.3 3.6 4.68E−02
Positive_regulation_of_fibroblast_proliferation(5) GO 10 2.3 4.3 4.68E−02
Interphase(4) GO 9 1.9 4.8 4.68E−02
Hair_follicle_morphogenesis(4) GO 7 1.2 6.0 4.68E−02
  1. Significant categories containing at least three times more genes than expected by chance. Provided are the category name, the database where data have been extracted, the number of targets genes of the 63 miRNAs of this category, the expected number of genes given the 2098 background genes, the enrichment factor, and the p value following adjustment for multiple testing